Published in Anticancer Agents Med Chem on January 01, 2007
Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genomics (2009) 1.91
Cellular responses to Cisplatin-induced DNA damage. J Nucleic Acids (2010) 1.82
Activation and involvement of p53 in cisplatin-induced nephrotoxicity. Am J Physiol Renal Physiol (2007) 1.70
Dibutyltin(IV) complexes containing arylazobenzoate ligands: chemistry, in vitro cytotoxic effects on human tumor cell lines and mode of interaction with some enzymes. Invest New Drugs (2009) 1.54
Structural basis of human DNA polymerase η-mediated chemoresistance to cisplatin. Proc Natl Acad Sci U S A (2012) 1.44
Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest (2011) 1.35
Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res (2008) 1.29
hMSH2 recruits ATR to DNA damage sites for activation during DNA damage-induced apoptosis. J Biol Chem (2011) 1.21
Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells. Cancer (2011) 1.21
Nuclear EGFR is required for cisplatin resistance and DNA repair. Am J Transl Res (2009) 1.19
Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. Br J Cancer (2010) 1.19
Platinum pathway. Pharmacogenet Genomics (2009) 1.12
Chemotherapy agent cisplatin induces 48-h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am J Physiol Regul Integr Comp Physiol (2009) 1.10
p53 hypersensitivity is the predominant mechanism of the unique responsiveness of testicular germ cell tumor (TGCT) cells to cisplatin. PLoS One (2011) 1.06
Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice. J Control Release (2013) 1.06
Rates of intercalator-driven platination of DNA determined by a restriction enzyme cleavage inhibition assay. J Biol Inorg Chem (2010) 1.01
Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One (2011) 1.01
[Pt(O,O'-acac)(gamma-acac)(DMS)], a new Pt compound exerting fast cytotoxicity in MCF-7 breast cancer cells via the mitochondrial apoptotic pathway. Br J Pharmacol (2007) 1.00
A high-throughput, homogeneous, bioluminescent assay for Pseudomonas aeruginosa gyrase inhibitors and other DNA-damaging agents. J Biomol Screen (2007) 1.00
Repair of DNA interstrand cross-links during S phase of the mammalian cell cycle. Environ Mol Mutagen (2010) 0.99
Cisplatin@US-tube carbon nanocapsules for enhanced chemotherapeutic delivery. Biomaterials (2011) 0.98
Mifepristone prevents repopulation of ovarian cancer cells escaping cisplatin-paclitaxel therapy. BMC Cancer (2012) 0.97
Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair. Mol Pharm (2011) 0.95
Peptide targeting of platinum anti-cancer drugs. Bioconjug Chem (2009) 0.94
Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. J Hematol Oncol (2011) 0.94
Mifepristone abrogates repopulation of ovarian cancer cells in between courses of cisplatin treatment. Int J Oncol (2009) 0.93
Cisplatin induces differentiation of breast cancer cells. Front Oncol (2013) 0.92
Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget (2014) 0.92
Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria function. Am J Physiol Renal Physiol (2013) 0.91
Pica as an adaptive response: Kaolin consumption helps rats recover from chemotherapy-induced illness. Physiol Behav (2009) 0.90
CCN2 enhances resistance to cisplatin-mediating cell apoptosis in human osteosarcoma. PLoS One (2014) 0.90
Fucoxanthin: a marine carotenoid exerting anti-cancer effects by affecting multiple mechanisms. Mar Drugs (2013) 0.89
Erk in kidney diseases. J Signal Transduct (2011) 0.89
Selective estrogen receptor modulator delivery of quinone warheads to DNA triggering apoptosis in breast cancer cells. ACS Chem Biol (2009) 0.85
Fucoxanthin enhances cisplatin-induced cytotoxicity via NFκB-mediated pathway and downregulates DNA repair gene expression in human hepatoma HepG2 cells. Mar Drugs (2013) 0.84
Activation of the human immune system by chemotherapeutic or targeted agents combined with the oncolytic parvovirus H-1. BMC Cancer (2011) 0.84
Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano (2013) 0.84
Non-invasive imaging of PI3K/Akt/mTOR signalling in cancer. Am J Nucl Med Mol Imaging (2012) 0.84
Novel Anticancer Platinum(IV) Complexes with Adamantylamine: Their Efficiency and Innovative Chemotherapy Strategies Modifying Lipid Metabolism. Met Based Drugs (2008) 0.83
The mechanism of mesna in protection from cisplatin-induced ovarian damage in female rats. J Gynecol Oncol (2013) 0.83
Signalling mechanisms involved in renal pathological changes during cisplatin-induced nephropathy. Eur J Clin Pharmacol (2013) 0.82
Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells. Oncotarget (2015) 0.82
Repopulation of ovarian cancer cells after chemotherapy. Cancer Growth Metastasis (2013) 0.82
Adding a combination of hydroxycitrate and lipoic acid (METABLOC™) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs (2010) 0.82
Rho kinase inhibitor Y-27632 facilitates recovery from experimental peripheral neuropathy induced by anti-cancer drug cisplatin. Neurotoxicology (2010) 0.82
Altered metabolism in head and neck squamous cell carcinoma: an opportunity for identification of novel biomarkers and drug targets. Head Neck (2011) 0.82
On the discovery, biological effects, and use of Cisplatin and metallocenes in anticancer chemotherapy. Bioinorg Chem Appl (2012) 0.81
Increased sensitivity of HPV-positive head and neck cancer cell lines to x-irradiation ± Cisplatin due to decreased expression of E6 and E7 oncoproteins and enhanced apoptosis. Am J Cancer Res (2015) 0.81
Sodium arsenite and hyperthermia modulate cisplatin-DNA damage responses and enhance platinum accumulation in murine metastatic ovarian cancer xenograft after hyperthermic intraperitoneal chemotherapy (HIPEC). J Ovarian Res (2011) 0.81
Complex and multifaceted therapy-related myeloid neoplasm following laryngeal cancer treated with Cisplatin and radiotherapy. Mediterr J Hematol Infect Dis (2013) 0.81
Immune Checkpoint Blockade: A New Paradigm in Treating Advanced Cancer. J Adv Pract Oncol (2015) 0.81
Cisplatin plus sodium arsenite and hyperthermia induces pseudo-G1 associated apoptotic cell death in ovarian cancer cells. Toxicol Sci (2014) 0.81
Neurotoxic 1-deoxysphingolipids and paclitaxel-induced peripheral neuropathy. FASEB J (2015) 0.80
Protein Kinase Cδ Suppresses Autophagy to Induce Kidney Cell Apoptosis in Cisplatin Nephrotoxicity. J Am Soc Nephrol (2016) 0.79
The effect of caffeine on cisplatin-induced apoptosis of lung cancer cells. Exp Hematol Oncol (2015) 0.79
Specific antioxidant compounds differentially modulate cytotoxic activity of doxorubicin and cisplatin: in vitro and in vivo study. Croat Med J (2014) 0.79
Sodium arsenite ± hyperthermia sensitizes p53-expressing human ovarian cancer cells to cisplatin by modulating platinum-DNA damage responses. Toxicol Sci (2012) 0.79
Labelling Herceptin with a novel oxaliplatin derivative: a computational approach towards the selective drug delivery. J Mol Model (2014) 0.78
Mechanical stress promotes cisplatin-induced hepatocellular carcinoma cell death. Biomed Res Int (2015) 0.78
Gap Junction Enhancer Potentiates Cytotoxicity of Cisplatin in Breast Cancer Cells. J Cancer Sci Ther (2012) 0.78
Lipocalin 2 Enhances Migration and Resistance against Cisplatin in Endometrial Carcinoma Cells. PLoS One (2016) 0.78
Preventing Damage Limitation: Targeting DNA-PKcs and DNA Double-Strand Break Repair Pathways for Ovarian Cancer Therapy. Front Oncol (2015) 0.78
DNA damage response in cisplatin-induced nephrotoxicity. Arch Toxicol (2015) 0.78
The physical and chemical stability of cisplatin (Teva) in concentrate and diluted in sodium chloride 0.9%. Contemp Oncol (Pozn) (2012) 0.78
Vitamin C in synergism with cisplatin induces cell death in cervical cancer cells through altered redox cycling and p53 upregulation. J Cancer Res Clin Oncol (2016) 0.77
Attenuation of Cisplatin-Induced Neurotoxicity by Cyanidin, a Natural Inhibitor of ROS-Mediated Apoptosis in PC12 Cells. Cell Mol Neurobiol (2015) 0.77
Reduced kidney lipoprotein lipase and renal tubule triglyceride accumulation in cisplatin-mediated acute kidney injury. Am J Physiol Renal Physiol (2012) 0.77
Pharmacokinetics of the perioperative use of cancer chemotherapy in peritoneal surface malignancy patients. Gastroenterol Res Pract (2012) 0.77
Synergistic effects of the sesquiterpene lactone, EPD, with cisplatin and paclitaxel in ovarian cancer cells. J Exp Clin Cancer Res (2015) 0.77
Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. J Control Release (2017) 0.77
Effects of Novel Dinuclear Cisplatinum(II) Complexes on the Electrical Properties of Human Molt-4 Leukemia Cells. Cell Biochem Biophys (2015) 0.76
Current evidence for the hepatoprotective activities of the medicinal mushroom Antrodia cinnamomea. Chin Med (2013) 0.76
Preclinical Assessment of Low Doses of Cisplatin in the Management of Acute Promyelocytic Leukemia. Int J Cancer Res Mol Mech (2015) 0.76
Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes. Mol Med Rep (2015) 0.76
Combined cisplatin and aurora inhibitor treatment increase neuroblastoma cell death but surviving cells overproduce BDNF. Biol Open (2016) 0.75
Synergic Effect of α-Mangostin on the Cytotoxicity of Cisplatin in a Cervical Cancer Model. Oxid Med Cell Longev (2016) 0.75
MCT1 promotes the cisplatin-resistance by antagonizing Fas in epithelial ovarian cancer. Int J Clin Exp Pathol (2015) 0.75
Metabolic interrogation as a tool to optimize chemotherapeutic regimens. Oncotarget (2017) 0.75
CTGF enhances resistance to 5-FU-mediating cell apoptosis through FAK/MEK/ERK signal pathway in colorectal cancer. Onco Targets Ther (2016) 0.75
DNA damage response in nephrotoxic and ischemic kidney injury. Toxicol Appl Pharmacol (2016) 0.75
Effects of novel dinuclear cisplatinum(II) complexes on the electric properties of human breast cancer cells. J Membr Biol (2013) 0.75
Evaluation of anti-metastatic potential of Cisplatin polymeric nanocarriers on B16F10 melanoma cells. Saudi Pharm J (2015) 0.75
Heat shock factor 1 induces crystallin-αB to protect against cisplatin nephrotoxicity. Am J Physiol Renal Physiol (2016) 0.75
Synergistic cytotoxicity of cisplatin and Taxol in overcoming Taxol resistance through the inhibition of LDHA in oral squamous cell carcinoma. Oncol Lett (2015) 0.75
Platinum-Based Drugs and DNA Interactions Studied by Single-Molecule and Bulk Measurements. Biophys J (2016) 0.75
Protective effect of bilberry (Vaccinium myrtillus L.) on cisplatin induced ovarian damage in rat. Cytotechnology (2013) 0.75
WEE1 inhibition targets cell cycle checkpoints for triple negative breast cancers to overcome cisplatin resistance. Sci Rep (2017) 0.75
Mitochondrial ClpP activity is required for cisplatin resistance in human cells. Biochim Biophys Acta (2015) 0.75
Cytotoxic Effects of Newly Synthesized Palladium(II) Complexes of Diethyldithiocarbamate on Gastrointestinal Cancer Cell Lines. Biochem Res Int (2014) 0.75
The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. Int J Mol Sci (2017) 0.75
Transition Metal Intercalators as Anticancer Agents-Recent Advances. Int J Mol Sci (2016) 0.75
MicroRNA-375 Is Induced in Cisplatin Nephrotoxicity to Repress Hepatocyte Nuclear Factor 1-β. J Biol Chem (2017) 0.75
Sildenafil potentiates the antitumor activity of cisplatin by induction of apoptosis and inhibition of proliferation and angiogenesis. Drug Des Devel Ther (2016) 0.75
Neuropeptide Y improves cisplatin-induced bone marrow dysfunction without blocking chemotherapeutic efficacy in a cancer mouse model. BMB Rep (2017) 0.75
The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials. Chem Soc Rev (2017) 0.75
Enhanced antitumor efficacy of cisplatin for treating ovarian cancer in vitro and in vivo via transferrin binding. Oncotarget (2017) 0.75
Platinum nanoparticles induce damage to DNA and inhibit DNA replication. PLoS One (2017) 0.75
MR image-guided delivery of cisplatin-loaded brain-penetrating nanoparticles to invasive glioma with focused ultrasound. J Control Release (2017) 0.75
DNA methylation protects against cisplatin-induced kidney injury by regulating specific genes, including interferon regulatory factor 8. Kidney Int (2017) 0.75
In vitro cytotoxic evaluation of novel dichlorodiorgano[N-(2-pyridylmethylene)arylamine]tin(IV) derivatives in human tumor cell lines. Invest New Drugs (2009) 0.75
APPL1 associates with TrkA and GIPC1 and is required for nerve growth factor-mediated signal transduction. Mol Cell Biol (2006) 1.78
Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev (2003) 1.59
Arginase I induction in macrophages, triggered by Th2-type cytokines, supports the growth of intracellular Leishmania parasites. Parasite Immunol (2002) 1.44
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study. J Acquir Immune Defic Syndr (2007) 1.43
SHP-1 negatively regulates neuronal survival by functioning as a TrkA phosphatase. J Cell Biol (2003) 1.12
Poly(ADP-ribose) polymerases: homology, structural domains and functions. Novel therapeutical applications. Prog Biophys Mol Biol (2005) 1.08
Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect (2008) 1.03
Programmed cell death in trypanosomatids: a way to maximize their biological fitness? Trends Parasitol (2004) 1.02
Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine (2004) 1.02
Development and validation of an automated high-throughput system for zebrafish in vivo screenings. PLoS One (2012) 1.01
Molecular mechanisms for the B-Z transition in the example of poly[d(G-C) x d(G-C)] polymers. A critical review. Chem Rev (2006) 0.98
The translational efficiencies of the two Leishmania infantum HSP70 mRNAs, differing in their 3'-untranslated regions, are affected by shifts in the temperature of growth through different mechanisms. J Biol Chem (2005) 0.97
Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect Immun (2005) 0.97
Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect (2003) 0.97
The heat shock proteins, Hsp70 and Hsp83, of Leishmania infantum are mitogens for mouse B cells. Cell Stress Chaperones (2002) 0.96
Nuclear localization signal-targeted poly(ethylene glycol) conjugates as potential carriers and nuclear localizing agents for carboplatin analogues. Bioconjug Chem (2004) 0.95
Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives. Curr Med Chem (2008) 0.94
Identification of an hepatitis delta virus-like ribozyme at the mRNA 5'-end of the L1Tc retrotransposon from Trypanosoma cruzi. Nucleic Acids Res (2011) 0.93
Thermodynamic stability of the C-terminal domain of the human inducible heat shock protein 70. Biochim Biophys Acta (2004) 0.92
The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect Immun (2003) 0.91
Poly(ADP-ribose) polymerase-1 inhibitor 3-aminobenzamide enhances apoptosis induction by platinum complexes in cisplatin-resistant tumor cells. Med Chem (2006) 0.90
Images in clinical medicine. Digital mucous cyst. N Engl J Med (2012) 0.90
H-ras and N-ras are dispensable for T-cell development and activation but critical for protective Th1 immunity. Blood (2011) 0.89
The expression of HSP83 genes in Leishmania infantum is affected by temperature and by stage-differentiation and is regulated at the levels of mRNA stability and translation. BMC Mol Biol (2004) 0.89
Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors in cancer chemotherapy. Recent Pat Anticancer Drug Discov (2006) 0.89
Recent advances in vaccines for leishmaniasis. Expert Opin Biol Ther (2004) 0.88
Synthetic sulfogalactosylceramide (sulfatide) and its use for the mass spectrometric quantitative urinary determination in metachromatic leukodystrophies. Glycoconj J (2007) 0.88
Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine (2008) 0.88
[Effectiveness of a multifactorial strategy for implementing clinical guidelines on unstable angina: cluster randomized trial]. Rev Esp Cardiol (2005) 0.87
Inhibition of Bacillus subtilis natural competence by a native, conjugative plasmid-encoded comK repressor protein. Environ Microbiol (2012) 0.87
Specific serodiagnosis of canine visceral leishmaniasis using Leishmania species ribosomal protein extracts. Clin Vaccine Immunol (2009) 0.86
Pharmacological modulation of Poly(ADP-ribose) polymerase-mediated cell death: exploitation in cancer chemotherapy. Mol Pharmacol (2003) 0.86
Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[PtCl(2)(OH)(2)(dimethylamine) (isopropylamine)]. Mol Pharmacol (2003) 0.85
Conserved nucleotides surrounding the trans-splicing acceptor site and the translation initiation codon in Leishmania genes. Exp Parasitol (2003) 0.85
Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge. Microbes Infect (2010) 0.85
The genetic immunization with paraflagellar rod protein-2 fused to the HSP70 confers protection against late Trypanosoma cruzi infection. Vaccine (2006) 0.85
Cell-cycle-dependent translation of histone mRNAs is the key control point for regulation of histone biosynthesis in Leishmania infantum. Biochem J (2004) 0.85
Antigenic properties of the Leishmania infantum GRP94 and mapping of linear B-cell epitopes. Immunol Lett (2002) 0.84
Adoptive transfer of dendritic cells pulsed with Leishmania infantum nucleosomal histones confers protection against cutaneous leishmaniosis in BALB/c mice. Microbes Infect (2007) 0.84
The biology and evolution of transposable elements in parasites. Trends Parasitol (2010) 0.84
Novel transplatinum(II) complexes with [N2O2] donor sets. Cellular pharmacology and apoptosis induction in Pam 212-ras cells. J Med Chem (2006) 0.83
Introns form compositional clusters in parallel with the compositional clusters of the coding sequences to which they pertain. J Mol Evol (2010) 0.82
Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines. Vaccine (2008) 0.81
BALB/c mice vaccinated with Leishmania major ribosomal proteins extracts combined with CpG oligodeoxynucleotides become resistant to disease caused by a secondary parasite challenge. J Biomed Biotechnol (2010) 0.81
Cross-protective effect of a combined L5 plus L3 Leishmania major ribosomal protein based vaccine combined with a Th1 adjuvant in murine cutaneous and visceral leishmaniasis. Parasit Vectors (2014) 0.81
Pentamidine is an antiparasitic and apoptotic drug that selectively modifies ubiquitin. Chem Biodivers (2005) 0.81
Risk of venous thromboembolic disease in women A qualitative systematic review. Eur J Obstet Gynecol Reprod Biol (2005) 0.80
A modified protocol for RNA isolation from high polysaccharide containing Cupressus arizonica pollen. Applications for RT-PCR and phage display library construction. Mol Biotechnol (2010) 0.80
Nucleic-acid-binding properties of the C2-L1Tc nucleic acid chaperone encoded by L1Tc retrotransposon. Biochem J (2009) 0.80
Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. Biochim Biophys Acta (2004) 0.80
High-efficiency plating method for Leishmania infantum. Mol Biochem Parasitol (2003) 0.79
Modulation of the humoral response to Dermatophagoides pteronyssinus allergens in BALB/c mice by extract modification and adjuvant use. Int Arch Allergy Immunol (2011) 0.79
Apoptosis induction and DNA interstrand cross-link formation by cytotoxic trans-[PtCl2(NH(CH3)2)(NHCH(CH3)2) : cross-linking between d(G) and complementary d(C) within oligonucleotide duplexes. Chembiochem (2002) 0.79
Characterization of an immunodominant antigenic epitope from Trypanosoma cruzi as a biomarker of chronic Chagas' disease pathology. Clin Vaccine Immunol (2011) 0.79
Synthesis and characterization of palladium(II) and platinum(II) complexes with Schiff bases derivatives of 2-pyridincarboxyaldehyde. Study of their interaction with DNA. J Inorg Biochem (2006) 0.78
Pr77 and L1TcRz: A dual system within the 5'-end of L1Tc retrotransposon, internal promoter and HDV-like ribozyme. Mob Genet Elements (2012) 0.77
Water soluble cationic trans-platinum complexes which induce programmed cell death in the protozoan parasite Leishmania infantum. J Inorg Biochem (2005) 0.77
Clinical and microbiological associations in chronic periodontitis. Acta Odontol Latinoam (2004) 0.77
The wide expansion of hepatitis delta virus-like ribozymes throughout trypanosomatid genomes is linked to the spreading of L1Tc/ingi clade mobile elements. BMC Genomics (2014) 0.77
Key role of the 3' untranslated region in the cell cycle regulated expression of the Leishmania infantum histone H2A genes: minor synergistic effect of the 5' untranslated region. BMC Mol Biol (2009) 0.77
Leishmania major infection in susceptible and resistant mice elicit a differential humoral response against a total soluble fraction and defined recombinant antigens of the parasite. Parasitol Res (2008) 0.77
Characterizing cellular immune response to kinetoplastid membrane protein-11 (KMP-11) during Leishmania (Viannia) panamensis infection using dendritic cells (DCs) as antigen presenting cells (APCs). Parasite Immunol (2003) 0.76
Synthesis, characterization, interaction with DNA and cytotoxicity of the new potential antitumour drug cis-K[Ru(eddp)Cl(2)]. J Inorg Biochem (2003) 0.76
Spanish regulatory approach for biobanking. Eur J Hum Genet (2012) 0.75
Structural and functional analysis of phi29 p16.7C dimerization mutants: identification of a novel aromatic cage dimerization motif. J Biol Chem (2007) 0.75
Detection of Leishmania infantum kinetoplast minicircle DNA by Real Time PCR in hair of dogs with leishmaniosis. Vet Parasitol (2012) 0.75
Molecular cloning and characterization of Cup a 4, a new allergen from Cupressus arizonica. Biochem Biophys Res Commun (2010) 0.75
Small amounts of urea and guanidine hydrochloride can be detected by a far-UV spectrophotometric method in dialysed protein solutions. J Biochem Biophys Methods (2004) 0.75
Crystalline structures as the only dermoscopic clue for the diagnosis of basal cell carcinoma. Arch Dermatol (2012) 0.75
Detection and chronology of parasitic kinetoplast DNA presence in hair of experimental Leishmania major infected BALB/c mice by Real Time PCR. Acta Trop (2013) 0.75
Diagnostic and therapeutic challenges. Retina (2011) 0.75
Analysis of calcium-induced conformational changes in calcium-binding allergens and quantitative determination of their IgE binding properties. Methods Mol Biol (2013) 0.75